Top 1% Retail Investors Load Up on Biotech Stocks Amid Market Rally

[Mirae Asset Securities Tally] Rznomics Tops Net Buying List

Finance|
|
By Lee Duk-yeon
|
null - Seoul Economic Daily Finance News from South Korea

The stocks most heavily net-bought by high-return investors trading through Mirae Asset Securities on the morning of the 27th were rgenomics, Woori Financial Group, and ABL Bio, in that order.

According to Mirae Asset Securities, "stock super-experts" — the top 1% of the firm's stock trading clients by investment returns over the past month — bought rgenomics the most by 11 a.m.

As of 11:51 a.m., rgenomics was trading at 192,000 won, up 3.67% from the previous session. The shares have been strong on the back of Phase 1 clinical results for its liver cancer treatment RZ-001, recently presented at the American Association for Cancer Research (AACR). According to rgenomics, a meaningful change in tumor size was measured when RZ-001 was administered in combination with the immuno-oncology drug Tecentriq and the targeted therapy Avastin. The company plans to expand global clinical trials for the drug and accelerate the development of follow-on pipelines.

Second-ranked Woori Financial Group saw heavy buying from top-performing investors despite a sharp drop in its share price. As of 11:59 a.m., Woori Financial Group was trading at 33,150 won, down 5.42% from the previous session. The stock plunged after the company announced earnings that significantly exceeded market consensus, and investors appear to have viewed the decline as a bargain-hunting opportunity.

Third-ranked ABL Bio was up 9.99%. Like rgenomics, the company is drawing attention for the performance of a drug candidate presented at AACR 2026. ABL Bio is developing a bispecific antibody-drug conjugate (ADC) that simultaneously targets two antigens expressed on cancer cells, and presented research results on a candidate currently in Phase 1 trials in the U.S. at AACR.

A securities industry official said, "Biotech companies' share prices can surge sharply when a drug candidate passes clinical trials or development succeeds, but investors should be cautious as they can also suffer losses in the opposite case."

The top net-sold stocks of the day were SK hynix, Hyundai Motor, and Mirae Asset Securities. On the previous trading day, the most net-bought stocks were OCI Holdings, Samsung Electro-Mechanics, and Samsung Electronics. The top net-sold stocks the previous day were Mirae Asset Securities, Woori Financial Group, and Hyundai Steel.

Mirae Asset Securities compiles the trading activity of the top 1% of its clients by returns over the past month and discloses the information on its mobile trading system (MTS) on a real-time, previous-day, and five-day basis. This statistical data is simple informational guidance unrelated to Mirae Asset Securities' opinions, and does not guarantee investment suitability or returns for individual investors. Investors should also be cautious as theme-related stocks may be subject to abnormal price swings.

Which candidate is the top pick for a technology export deal from AACR 2026?

null - Seoul Economic Daily Finance News from South Korea

AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.